Stocks TelegraphStocks Telegraph
Stock Ideas

NRIX Company Profile and Key Details

NASDAQ : NRIX

Nurix Therapeutics

$15.30
-0.34-2.17%
At Close 4:00 PM
59.19
BESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

Nurix Therapeutics, Inc. (NRIX) stock declined over -2.17%, trading at $15.30 on NASDAQ, down from the previous close of $15.64. The stock opened at $15.82, fluctuating between $15.17 and $16.12 in the recent session.

Stock Snapshot

15.64
Prev. Close
1.33B
Market Cap
15.17
Day Low
-4.83
P/E Ratio
-3.17
EPS (TTM)
-1.62
Cash Flow per Share
15.82
Open
86.67M
Number of Shares
16.115
Day High
98.01%
Free Float in %
3.07
Book Value
2.53M
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jun 10, 202615.8016.1115.1715.302.53M
Jun 09, 202616.0016.9914.6715.646.65M
Jun 08, 202616.7318.2015.3615.6421M
Jun 05, 202615.3115.5814.2414.641.63M
Jun 04, 202615.6715.9115.2615.281.58M
Jun 03, 202616.3116.3415.4315.481.3M
Jun 01, 202617.7317.7316.8517.39851.62K
May 29, 202617.6718.0017.5617.761.16M
May 28, 202617.4717.7717.1617.67866.27K
May 27, 202617.4618.1017.0817.47831.13K
May 26, 202617.5517.8217.0817.381.03M
May 22, 202617.5417.8517.3217.501.05M
May 21, 202616.2017.7316.0017.531.96M
May 20, 202615.3516.5015.3216.421.67M
May 19, 202615.3415.6715.0715.241.06M
May 18, 202615.9116.5015.5015.512.19M
May 15, 202615.7816.1615.5915.861M
May 14, 202616.1816.2715.7416.00529.13K
May 13, 202615.9616.4515.7516.18979.11K
May 12, 202616.3016.4915.7015.96658.72K

Contact Details

San Francisco, CA 94158

United States

https://www.nurixtx.com415 660 5320

About Company

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Company Information

Employees286
Beta2.02
Sales or Revenue$54.55M
5Y Sales Change%-0.391%
Fiscal Year EndsNovember
SectorHealthcare
IndustryBiotechnology

Stock Peers

ARGX
-21.82-2.47%
argenx SE$862.18REGN
-14.53-2.36%
Regeneron Pharmaceuticals, Inc.$601.65UTHR
-9.04-1.63%
United Therapeutics Corporation$544.10MDGL
-5.57-1.17%
Madrigal Pharmaceuticals, Inc.$471.32VRTX
-10.06-2.26%
Vertex Pharmaceuticals Incorporated$435.71KRTX
0.09+0.03%
Karuna Therapeutics, Inc.$329.83KRYS
2.66+0.86%
Krystal Biotech, Inc.$312.41ALNY
-6.47-2.17%
Alnylam Pharmaceuticals, Inc.$291.22LGND
4.96+2.04%
Ligand Pharmaceuticals Incorporated$248.24AXSM
0.7+0.28%
Axsome Therapeutics, Inc.$246.34

Company Overview

Nurix Therapeutics, Inc. (NASDAQ:NRIX) closed at $15.30 USD, losing -$0.34 (-2.17%) from the previous close of $15.64. The stock is currently mid-range between its 52-week high and low $8.20 and $22.50. With a market capitalization of about $1.33 billion, Nurix Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.87). Key stats such as the average daily volume over the past year has been around 1.59 million shares, trading with heavier-than-usual volume. Headquartered in San Francisco, CA, Nurix Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Arthur T. Sands, the company employs approximately 286 people and listed since July 24, 2020. Nurix Therapeutics, Inc., a biopharmaceutical firm headquartered in San Francisco, California, was founded in 2009.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -0.53%, SMA50 -9.11%, SMA200 22.88%). The stock’s 14-day RSI is 45.28 (neutral), while the ATR of 0.9 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -28.4% below its high and over 96.94% above its low. Average 10-day trading volume of 5.08 million shares is significantly above the 3-month average of 1.63 million, indicating heightened recent market interest.

Valuation Metrics

Nurix Therapeutics, Inc. trades at a P/E ratio of -5.69, slightly below the S&P 500 average, with a price-to-sales ratio of 18.44 and a price-to-book ratio of 3.5 trading at moderately above to book value. The P/FCF stands at -4.87, also below market averages.

Dividend & Fair Value

Nurix Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$6.28. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Nurix Therapeutics, Inc. generated EPS of -$3.04 over the past year. Five-year average earnings growth is -2.04%. Wall Street analysts project EPS growth of 6.26% annually over the next five years. The latest quarter delivered EPS of -$0.79. The next quarter is forecast at -$0.76. Next year's EPS is expected at -$28.83. Analyst sentiment is bullish. Analyst rating data shows there are 15 Strong Buy ratings, 29 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $15.00. The high target offers 194.12% upside. The low target suggests -1.96% downside. The mean target is $29.33. This offers 91.7% upside. Nurix Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended April 08, 2026, missed forecasts by 3.95%. The prior quarter beat by -2.38%. Over the last six quarters, Apple has recorded several small beats. These include 11.94% in January 28, 2025.

Shareholding & Insider Activity

Nurix Therapeutics, Inc. has 76.45 million shares outstanding. The public float is 61.46 million shares, elevated short interest at 20.03% of float. This equals 13.03 million shares. The short ratio is 13.42 days. Institutional investors hold 116.68% of the float. Insiders own 1.43%. Hansen Gwenn holds 120.40 thousand shares, van Houte Hans has 37.59 thousand shares and Ring Christine has 13.58 thousand shares. Over the past six months, insider transactions show net selling. They sold 65.86 thousand shares across 15 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Nurix Therapeutics generated $54.55M in revenue, or $0.81 per share. Gross margin was 100.00%, operating margin -390.52%, and net profit margin -354.85%. Returns are negative, with ROA at -53.10% and ROE at -96.55%.
On valuation metrics, Nurix Therapeutics trades at a P/E of -5.69, P/S of 18.44 and P/B of 3.50. The current ratio is 6.01 and quick ratio is 6.01. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -9.66 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.12, supported by a cash flow-to-debt ratio of -4.44.

Quarterly Financial Highlights

For the quarter ended Nov 30, 2024, Nurix Therapeutics posted revenue of $54.55M, down slightly from $76.99M in the prior quarter. Gross profit was $54.55M (margin 100.00%). Operating income was - $213.03M (margin -390.5%). Net income was- $193.57M (EPS - $2.88).
The company ended the quarter with $287.91M in cash and short-term investments, a total debt of $30.61M, and net debt of - $24.01M. Total assets were $364.54M, with equity of $200.49M. Financials further reflected weakness, with operating cash flow of - $81.37M, free cash flow of - $89.77M, and capital expenditures of - $8.40M.

Frequently Asked Questions

What is the current Nurix Therapeutics, Inc. (NRIX) stock price?
Nurix Therapeutics, Inc. (NASDAQ: NRIX) stock price is $15.30 in the last trading session. During the trading session, NRIX stock reached the peak price of $16.12 while $15.17 was the lowest point it dropped to. The percentage change in NRIX stock occurred in the recent session was -2.17% while the dollar amount for the price change in NRIX stock was - $0.34.
NRIX's industry and sector of operation?
The NASDAQ listed NRIX is part of Biotechnology industry that operates in the broader Healthcare sector. Nurix Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of NRIX?
Mr. Howard A. Simon J.D., Esq., SPHR
Vice President of Operations & Corporation Counsel
Dr. Christine Ring
Gen. Counsel & Sec.
Rita Kwong
Senior Accounting Mang.
Mr. Howard A. Simon Esq., J.D., SPHR
Vice President of Operations & Corporation Counsel
Ms. Stefani A. Wolff
Chief Operating Officer & Executive Vice President of Product Devel.
Dr. Gwenn M. Hansen Ph.D.
Chief Scientific Officer
Dr. Arthur T. Sands M.D., Ph.D.
Chief Executive Officer, Pres & Director
Mr. Johannes Van Houte
Chief Financial Officer
Dr. John Kuriyan Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Michael Rapé Ph.D.
Founder & Member of Scientific Advisory Board
Prof. Arthur Weiss M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Mr. Eric C. Schlezinger J.D.
Chief People Officer
Dr. Arthur Weiss M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Michael T. Lotze F.A.C.S., M.D.
Chief Cellular Therapy Officer
Dr. Christine Ring J.D., Ph.D.
Gen. Counsel & Sec.
Dr. Jason Kantor Ph.D.
Executive Vice President of Fin. & Bus. Strategy
How NRIX did perform over past 52-week?
NRIX's closing price is 86.7% higher than its 52-week low of $8.20 where as its distance from 52-week high of $22.50 is -32%.
How many employees does NRIX have?
Number of NRIX employees currently stands at 286.
Link for NRIX official website?
Official Website of NRIX is: https://www.nurixtx.com
How do I contact NRIX?
NRIX could be contacted at phone 415 660 5320 and can also be accessed through its website. NRIX operates from 1700 Owens Street, San Francisco, CA 94158, United States.
How many shares of NRIX are traded daily?
NRIX stock volume for the day was 2.53M shares. The average number of NRIX shares traded daily for last 3 months was 1.59M.
What is the market cap of NRIX currently?
The market value of NRIX currently stands at $1.33B with its latest stock price at $15.30 and 86.67M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings CalendarStocks Watchlist
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph